BIOMARIN PHARMACEUTICAL INC (BMRN) Share-based Payment Arrangement, Expense USD 2010 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Biomarin Pharmaceutical Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to 2024.
Biomarin Pharmaceutical Inc Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $58.2 M, a 8.48% increase year-over-year.
Biomarin Pharmaceutical Inc Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $212 M, a 4.69% increase year-over-year.
Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2023 was $207 M, a 5.5% increase from 2022.
Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2022 was $196 M, a 0.48% decline from 2021.
Biomarin Pharmaceutical Inc annual Share-based Payment Arrangement, Expense for 2021 was $197 M, a 3.98% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly Data (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q1 2024	$212 M	$58.2 M	+$4.55 M	+8.48%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-04-26
Q4 2023	$207 M	$54.9 M	+$8.12 M	+17.4%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-26
Q3 2023	$199 M	$48.4 M	-$6.28 M	-11.5%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-02
Q2 2023	$205 M	$50.2 M	+$3.08 M	+6.55%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-02
Q1 2023	$202 M	$53.7 M	+$5.86 M	+12.3%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-04-26
Q4 2022	$196 M	$46.7 M	+$2.84 M	+6.48%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-26
Q3 2022	$193 M	$54.7 M	+$5.64 M	+11.5%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-02
Q2 2022	$188 M	$47.1 M	-$7.77 M	-14.2%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-02
Q1 2022	$196 M	$47.8 M	-$1.67 M	-3.37%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-04-28
Q4 2021	$197 M	$43.9 M	-$3.7 M	-7.77%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-26
Q3 2021	$201 M	$49 M	-$1.14 M	-2.28%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-10-28
Q2 2021	$202 M	$54.8 M	+$9.88 M	+22%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$192 M	$49.5 M	+$2.51 M	+5.34%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-04-29
Q4 2020	$190 M	$47.6 M	+$9.48 M	+24.9%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-27
Q3 2020	$180 M	$50.2 M	+$11 M	+28.1%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-10-29
Q2 2020	$169 M	$45 M	+$5.13 M	+12.9%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-07-30
Q1 2020	$164 M	$47 M	+$4.23 M	+9.9%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-04-30
Q4 2019	$160 M	$38.1 M	+$1.54 M	+4.22%	Oct 1, 2019	Dec 31, 2019	10-K	2022-02-25
Q3 2019	$158 M	$39.2 M	+$2.13 M	+5.74%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-06
Q2 2019	$156 M	$39.8 M	+$1.22 M	+3.17%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-05
Q1 2019	$155 M	$42.8 M	+$6.15 M	+16.8%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-01
Q4 2018	$149 M	$36.6 M	+$2.97 M	+8.86%	Oct 1, 2018	Dec 31, 2018	10-K	2021-02-26
Q3 2018	$146 M	$37 M	+$1.14 M	+3.18%	Jul 1, 2018	Sep 30, 2018	10-Q/A	2019-11-04
Q2 2018	$145 M	$38.6 M	-$1.5 M	-3.73%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-02
Q1 2018	$146 M	$36.6 M	+$5.93 M	+19.3%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-04-29
Q4 2017	$140 M	$33.6 M	-$4.08 M	-10.8%	Oct 1, 2017	Dec 31, 2017	10-K	2020-02-27
Q3 2017	$144 M	$35.9 M	+$3 M	+9.12%	Jul 1, 2017	Sep 30, 2017	10-Q	2018-10-26
Q2 2017	$141 M	$40.1 M	+$6.2 M	+18.3%	Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-03
Q1 2017	$135 M	$30.7 M	+$497 K	+1.65%	Jan 1, 2017	Mar 31, 2017	10-Q	2018-04-27
Q4 2016	$135 M	$37.7 M	+$7.1 M	+23.2%	Oct 1, 2016	Dec 31, 2016	10-K	2019-02-28
Q3 2016	$128 M	$32.9 M	+$4.14 M	+14.4%	Jul 1, 2016	Sep 30, 2016	10-Q	2017-10-31
Q2 2016	$123 M	$33.9 M	+$4.39 M	+14.9%	Apr 1, 2016	Jun 30, 2016	10-Q	2017-08-02
Q1 2016	$119 M	$30.2 M	+$7.49 M	+33%	Jan 1, 2016	Mar 31, 2016	10-Q	2017-05-04
Q4 2015	$112 M	$30.6 M	-$2.29 M	-6.96%	Oct 1, 2015	Dec 31, 2015	10-K	2018-02-26
Q3 2015	$114 M	$28.8 M	+$8.75 M	+43.8%	Jul 1, 2015	Sep 30, 2015	10-Q	2016-11-03
Q2 2015	$105 M	$29.5 M	+$12.3 M	+71.1%	Apr 1, 2015	Jun 30, 2015	10-Q	2016-08-08
Q1 2015	$92.8 M	$22.7 M	+$6.39 M	+39.2%	Jan 1, 2015	Mar 31, 2015	10-Q	2016-05-02
Q4 2014	$86.4 M	$32.9 M	+$10.2 M	+44.9%	Oct 1, 2014	Dec 31, 2014	10-K	2017-02-27
Q3 2014	$76.2 M	$20 M	+$3.8 M	+23.4%	Jul 1, 2014	Sep 30, 2014	10-Q	2015-11-02
Q2 2014	$72.4 M	$17.3 M	+$3.32 M	+23.8%	Apr 1, 2014	Jun 30, 2014	10-Q	2015-08-05
Q1 2014	$69.1 M	$16.3 M	+$4.74 M	+41%	Jan 1, 2014	Mar 31, 2014	10-Q	2015-05-05
Q4 2013	$64.4 M	$22.7 M	+$10.6 M	+88%	Oct 1, 2013	Dec 31, 2013	10-K	2016-02-29
Q3 2013	$53.8 M	$16.2 M	+$4.07 M	+33.5%	Jul 1, 2013	Sep 30, 2013	10-Q	2014-10-28
Q2 2013	$49.7 M	$13.9 M	+$1.29 M	+10.2%	Apr 1, 2013	Jun 30, 2013	10-Q	2014-07-31
Q1 2013	$48.4 M	$11.6 M	+$431 K	+3.87%	Jan 1, 2013	Mar 31, 2013	10-Q	2014-05-02
Q4 2012	$48 M	$12.1 M	+$848 K	+7.56%	Oct 1, 2012	Dec 31, 2012	10-K	2015-03-02
Q3 2012	$47.1 M	$12.1 M	+$521 K	+4.48%	Jul 1, 2012	Sep 30, 2012	10-Q	2013-10-28
Q2 2012	$46.6 M	$12.6 M	+$2.03 M	+19.1%	Apr 1, 2012	Jun 30, 2012	10-Q	2013-07-29
Q1 2012	$44.6 M	$11.1 M	+$754 K	+7.26%	Jan 1, 2012	Mar 31, 2012	10-Q	2013-04-29
Q4 2011	$43.8 M	$11.2 M			Oct 1, 2011	Dec 31, 2011	10-K	2014-02-26
Q3 2011		$11.6 M	+$1.66 M	+16.7%	Jul 1, 2011	Sep 30, 2011	10-Q	2012-10-29
Q2 2011		$10.6 M	+$1.44 M	+15.7%	Apr 1, 2011	Jun 30, 2011	10-Q	2012-08-02
Q1 2011		$10.4 M			Jan 1, 2011	Mar 31, 2011	10-Q	2012-04-30
Q3 2010		$9.96 M			Jul 1, 2010	Sep 30, 2010	10-Q	2011-10-31
Q2 2010		$9.17 M			Apr 1, 2010	Jun 30, 2010	10-Q	2011-08-01

* An asterisk sign (*) next to the value indicates that the value is likely invalid.